DK3365438T3 - Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser - Google Patents

Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser Download PDF

Info

Publication number
DK3365438T3
DK3365438T3 DK16794111.1T DK16794111T DK3365438T3 DK 3365438 T3 DK3365438 T3 DK 3365438T3 DK 16794111 T DK16794111 T DK 16794111T DK 3365438 T3 DK3365438 T3 DK 3365438T3
Authority
DK
Denmark
Prior art keywords
codon
applications
treatment
reduced size
copper transport
Prior art date
Application number
DK16794111.1T
Other languages
English (en)
Inventor
Stephen G Kaler
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK3365438T3 publication Critical patent/DK3365438T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03004Cu2+-exporting ATPase (3.6.3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK16794111.1T 2015-10-21 2016-10-21 Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser DK3365438T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562244594P 2015-10-21 2015-10-21
PCT/US2016/058124 WO2017070472A1 (en) 2015-10-21 2016-10-21 Codon-optimized reduced-size atp7a cdna and uses for treatment of copper transport disorders

Publications (1)

Publication Number Publication Date
DK3365438T3 true DK3365438T3 (da) 2021-07-12

Family

ID=57256420

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16794111.1T DK3365438T3 (da) 2015-10-21 2016-10-21 Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser

Country Status (12)

Country Link
US (2) US10988778B2 (da)
EP (1) EP3365438B1 (da)
JP (2) JP6854286B2 (da)
CN (1) CN108431216B (da)
AU (1) AU2016341983B8 (da)
CA (1) CA3001574A1 (da)
DK (1) DK3365438T3 (da)
ES (1) ES2879400T3 (da)
HU (1) HUE054802T2 (da)
PL (1) PL3365438T3 (da)
PT (1) PT3365438T (da)
WO (1) WO2017070472A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820462A4 (en) * 2018-07-12 2022-04-27 The Texas A&M University System COMPOSITIONS FOR TREATMENT OF COPPER DEFICIENCY AND METHODS OF USE
CN117042764A (zh) * 2021-03-18 2023-11-10 塞普鲁姆治疗公司 组氨酸铜组合物和其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017321A1 (en) 1992-02-25 1993-09-02 Unisearch Limited Electrothermal atomic absorption and preconcentration device
DE606516T1 (de) 1993-01-13 1995-03-16 Idemitsu Kosan Co Gegen menschlichen Ceruloplasmin monoklonaler Antikörper.
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
KR100459644B1 (ko) 2001-03-31 2004-12-03 제노백(주) 혈액 여과지에서의 효소면역측정법을 이용한셀룰로플라스민 농도 측정 방법 및 이 방법을 이용한윌슨병 스크리닝 검사용 키트와 진단 시약
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20070161120A1 (en) 2006-01-10 2007-07-12 Viorica Lopez-Avila Ceruloplasmin Assay
AU2007245181A1 (en) * 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
DK2242840T3 (da) 2008-01-29 2019-10-21 Applied Genetic Tech Corporation Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension
WO2010042102A1 (en) 2008-10-06 2010-04-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of subjects likely to benefit from copper treatment
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
WO2010114948A2 (en) 2009-04-02 2010-10-07 University Of Florida Research Foundation, Inc. An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors
CN104520428B (zh) * 2012-02-17 2018-09-21 费城儿童医院 将基因转移到细胞、器官和组织的aav载体组合物和方法
CA2868391A1 (en) * 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease

Also Published As

Publication number Publication date
JP2021052796A (ja) 2021-04-08
CN108431216A (zh) 2018-08-21
EP3365438A1 (en) 2018-08-29
AU2016341983B8 (en) 2022-10-06
AU2016341983A1 (en) 2018-04-26
WO2017070472A1 (en) 2017-04-27
AU2016341983B2 (en) 2022-05-26
HUE054802T2 (hu) 2021-09-28
PL3365438T3 (pl) 2021-10-18
PT3365438T (pt) 2021-07-12
EP3365438B1 (en) 2021-04-28
JP2018533941A (ja) 2018-11-22
AU2016341983A8 (en) 2022-10-06
US20180312871A1 (en) 2018-11-01
CN108431216B (zh) 2022-08-05
US10988778B2 (en) 2021-04-27
JP6854286B2 (ja) 2021-04-07
ES2879400T3 (es) 2021-11-22
US20210214751A1 (en) 2021-07-15
CA3001574A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
ZA201901732B (en) Card handling devices and related assemblies and components
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3322804T3 (da) Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf
GB2538522B (en) Electronic circuit and component construction
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
DK3432899T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis
TWI563376B (en) Assembled structure and electronic apparatus used for chip powering
DK2964255T3 (da) Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK3067575T3 (da) Skrue til undgåelse af revner og grater
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
HK1259545A1 (zh) 用於治療癌症的bcl-2抑制劑和mek抑制劑組合產品
DK3297654T3 (da) Behandling af post-bariatrisk hypoglykæmi med exendin(9-39)
DK3270909T3 (da) Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko
DK2991507T3 (da) Anvendelse af en sammensætning omfattende fiskeolie og juice til behandling og/eller efterbehandling af cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3297651T3 (da) Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf
DK3326635T3 (da) Behandling og forebyggelse af forkølelse ved hjælp af povidon-iod
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
HK1225682A1 (zh) 終端和服務器
DK3678692T3 (da) Genotypestratificering ved behandling og forebyggelse af diabetes
GB201510606D0 (en) Integrated circuit inputs and outputs
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment